In Brief: FDA Orthopedic and Rehabilitation Devices Panel
This article was originally published in The Gray Sheet
FDA Orthopedic and Rehabilitation Devices Panel: Jan. 12 meeting at FDA's Parklawn Building in Rockville, Maryland, will address reclassification petitions for non- and semi-constrained shoulders and uni- and total-patellofemorotibial knees. On Jan. 13, the advisory committee will discuss petitions on patellofemoral knees and constrained elbows, as well as classification of calcium sulfate pre-formed pellets (plaster of paris pellets). Written submissions for presentation at the meeting are due by Jan. 5; for more information contact panel secretary Jodi Nashman at 301/594-2036...
You may also be interested in...
House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”